140 related articles for article (PubMed ID: 28776422)
1. Isotonic designs for phase I trials in partially ordered groups.
Conaway M
Clin Trials; 2017 Oct; 14(5):491-498. PubMed ID: 28776422
[TBL] [Abstract][Full Text] [Related]
2. A design for phase I trials in completely or partially ordered groups.
Conaway MR
Stat Med; 2017 Jul; 36(15):2323-2332. PubMed ID: 28384843
[TBL] [Abstract][Full Text] [Related]
3. Shift models for dose-finding in partially ordered groups.
Horton BJ; Wages NA; Conaway MR
Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
[TBL] [Abstract][Full Text] [Related]
4. Designs for phase I trials in ordered groups.
Conaway MR; Wages NA
Stat Med; 2017 Jan; 36(2):254-265. PubMed ID: 27624880
[TBL] [Abstract][Full Text] [Related]
5. Phase I design for completely or partially ordered treatment schedules.
Wages NA; O'Quigley J; Conaway MR
Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
[TBL] [Abstract][Full Text] [Related]
6. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
Guo B; Li Y
Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
[TBL] [Abstract][Full Text] [Related]
7. Revisiting isotonic phase I design in the era of model-assisted dose-finding.
Wages NA; Conaway MR
Clin Trials; 2018 Oct; 15(5):524-529. PubMed ID: 30101616
[TBL] [Abstract][Full Text] [Related]
8. Isotonic designs for phase I cancer clinical trials with multiple risk groups.
Yuan Z; Chappell R
Clin Trials; 2004; 1(6):499-508. PubMed ID: 16279290
[TBL] [Abstract][Full Text] [Related]
9. A hybrid Bayesian adaptive design for dose response trials.
Chang M; Chow SC
J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
[TBL] [Abstract][Full Text] [Related]
10. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
11. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
12. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Zang Y; Lee JJ
Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
[TBL] [Abstract][Full Text] [Related]
13. Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework.
Doussau A; Asselain B; Le Deley MC; Geoerger B; Doz F; Vassal G; Paoletti X
Contemp Clin Trials; 2012 Jul; 33(4):657-65. PubMed ID: 22521954
[TBL] [Abstract][Full Text] [Related]
14. Competing designs for drug combination in phase I dose-finding clinical trials.
Riviere MK; Dubois F; Zohar S
Stat Med; 2015 Jan; 34(1):1-12. PubMed ID: 24464821
[TBL] [Abstract][Full Text] [Related]
15. Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.
Xue X; Foster MC; Ivanova A
J Biopharm Stat; 2019; 29(4):625-634. PubMed ID: 31251112
[TBL] [Abstract][Full Text] [Related]
16. An adaptive model switching approach for phase I dose-finding trials.
Daimon T; Zohar S
Pharm Stat; 2013; 12(4):225-32. PubMed ID: 23801550
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
18. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
Potter DM
Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
[TBL] [Abstract][Full Text] [Related]
19. The quasi-CRM shift method for partially ordered groups.
Celum C; Horton BJ; Conaway M
Contemp Clin Trials; 2024 Jan; 136():107400. PubMed ID: 38000453
[TBL] [Abstract][Full Text] [Related]
20. An integrated dose-finding tool for phase I trials in oncology.
Yang S; Wang SJ; Ji Y
Contemp Clin Trials; 2015 Nov; 45(Pt B):426-434. PubMed ID: 26419937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
